整合素 α9β1 信号通路在器官纤维化中的研究进展

肖婷 ,  昝欣玙 ,  刘静雯 ,  买尔毕亚·艾尔肯 ,  侯君洁 ,  张芝平 ,  王亚茹

国际老年医学杂志 ›› 2026, Vol. 47 ›› Issue (6) : 808 -810.

PDF (1225KB)
国际老年医学杂志 ›› 2026, Vol. 47 ›› Issue (6) : 808 -810. DOI: 10.3969/j.issn.1674-7593.2026.06.017
综述

整合素 α9β1 信号通路在器官纤维化中的研究进展

作者信息 +

Research advances of the integrin α 9β 1 signaling pathway in organ fibrosis

Author information +
文章历史 +
PDF (1253K)

摘要

含 sushi 结构域、 血管性血友病因子 A 型结构域、 表皮生长因子结构域和正五聚蛋白结 构域的蛋白质 1 (Svep1) 是整合素 α9β1 亲和力最高的配体之一, 血管细胞黏附分子-1 (VCAM-1) 亦为 整合素 α9β1 的重要配体, 二者分别通过与 α9β1 相互作用参与不同类型细胞的功能调控, 如调节免疫细胞 黏附迁移、 促进成纤维细胞活化及细胞外基质沉积等, 进而影响肝、 肺、 心、 肾等多器官纤维化的发生 发展。 器官纤维化是多种慢性炎症性疾病的终末期病理改变, 现有治疗手段有限。 本文系统梳理整合素 α9β1 及其主要配体的结构、 功能及信号调控特点, 总结其在多器官纤维化中的作用, 为机制及干预策略 的研究提供理论依据和启发。

Abstract

Svep1, a protein containing sushi, von Willebrand factor type A, epidermal growth factor, and pentraxin do- mains, is one of the highest-affinity ligands for integrin α9β1, and VCAM-1 is another important ligand. Through their interactions with α9β1, these ligands regulate diverse cellular functions, including immune cell adhesion and migration, fibroblast activation, and extra- cellular matrix deposition, thereby contributing to fibrosis in multiple organs such as the liver, lung, heart, and kidney. Organ fibrosis represents the end-stage pathology of many chronic inflammatory diseases, yet current therapies are limited. This review summarizes the structure, function, and signaling properties of integrin α9β1 and its major ligands, as well as their roles in multi-organ fibrosis, aiming to provide a basis and direction for future mechanistic and therapeutic research.

关键词

Svep1-整合素 α9β1 信号通路 / 器官纤维化 / 细胞外基质 / 炎症反应 / 成纤维细胞活化

Key words

Svep1-Integrin α9β1 signaling pathway / Organ fibrosis / Extracellular matrix / Inflammatory response / Fibroblast activation

引用本文

引用格式 ▾
肖婷,昝欣玙,刘静雯,买尔毕亚·艾尔肯,侯君洁,张芝平,王亚茹. 整合素 α9β1 信号通路在器官纤维化中的研究进展[J]. 国际老年医学杂志, 2026, 47(6): 808-810 DOI:10.3969/j.issn.1674-7593.2026.06.017

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

Parola M, Pinzani M . Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues[J]. Mol Aspects Med, 2019, 65: 37-55.

[2]

Karsdal M A, Manon-Jensen T, Genovese F, et al. Novel insights into the function and dynamics of extracellular matrix in liver fibrosis [J]. Am J Physiol Gastrointest Liver Physiol, 2015, 308(10): G807-G830.

[3]

Ni Y, Huang M, Chen S, et al. Integrins and NAFLD-associated liver diseases: clinical associations, patho- physiological mechanisms and pharmacological implica- tions[J]. Acta Biochim Biophys Sin, 2024, 56(11): 1573-1583.

[4]

Guo Q, Furuta K, Lucien F, et al. Integrin β1-enriched extracellular vesicles mediate monocyte adhesion and pro- mote liver inflammation in murine NASH[J]. J Hepatol, 2019, 71(6): 1193-1205.

[5]

Nishimichi N, Higashikawa F, Kinoh H H, et al. Poly- meric osteopontin employs integrin α9β1 as a receptor and attracts neutrophils by presenting a de novo binding site [J]. J Biol Chem, 2009, 284(22): 14769-14776.

[6]

Cui G, Chen J, Wu Z, et al. Thrombin cleavage of os- teopontin controls activation of hepatic stellate cells and is essential for liver fibrogenesis[J]. J Cell Physiol, 2019, 234(6): 8988-8997.

[7]

Olsen A L, Sackey B K, Marcinkiewicz C, et al. Fi- bronectin extra domain-a promotes hepatic stellate cell motility but not differentiation into myofibroblasts [J]. Gastroenterology, 2012, 142(4): 928-937. e3.

[8]

Lee U E, Friedman S L. Mechanisms of hepatic fibrogen- esis[J]. Best Pract Res Clin Gastroenterol, 2011, 25 (2): 195-206.

[9]

Ye D, Ding M, Song Y M, et al. Liver developmental microenvironment promotes iHSC generation from human iPSCs[J]. Sci Rep, 2025, 15: 22338.

[10]

Ye B, Shen Y, Chen H, et al. Differential proteomic a- nalysis of plasma-derived exosomes as diagnostic biomar- kers for chronic HBV-related liver disease[J]. Sci Rep, 2022, 12: 14428.

[11]

Wijsenbeek M, Suzuki A, Maher T M . Interstitial lung diseases[J]. Lancet, 2022, 400(10354): 769-786.

[12]

Bi Z, Zang G, Wang X, et al. Integrins and pulmonary fibrosis: pathogenic roles and therapeutic opportunities [J]. Biomol Biomed, 2025, 26(2): 200-214.

[13]

Mambole A, Bigot S, Baruch D, et al. Human neutro- phil integrin α9β1: up-regulation by cell activation and synergy with β2 integrins during adhesion to endothelium under flow [J]. J Leukoc Biol, 2010, 88(2): 321-327.

[14]

Saldanha-Gama R F, Moraes J A, Mariano-Oliveira A, et al. α9β1 integrin engagement inhibits neutrophil spon- taneous apoptosis: involvement of Bcl-2 family members [J]. Biochim Biophys Acta BBA Mol Cell Res, 2010, 1803(7): 848-857.

[15]

Gray R D, Hardisty G, Regan K H, et al. Delayed neu- trophil apoptosis enhances NET formation in cystic fibro- sis[J]. Thorax, 2018, 73(2): 134-144.

[16]

Yan S, Li M, Liu B, et al. Neutrophil extracellular traps and pulmonary fibrosis: an update [ J ]. J Inflamm, 2023, 20(1): 2.

[17]

Andrews S L, Ghaderi-Najafabadi M, Gong P, et al. SVEP1 influences monocyte to macrophage differentiation via integrin α4β1/α9β1 and Rho/ Rac signalling [J]. Biochim Biophys Acta BBA Mol Cell Res, 2023, 1870 (6): 119479.

[18]

Cheng P, Li S, Chen H. Macrophages in lung injury, repair, and fibrosis[J]. Cells, 2021, 10(2): 436.

[19]

Chen C, Kudo M, Rutaganira F, et al. Integrin α9β1 in airway smooth muscle suppresses exaggerated airway nar- rowing [J]. J Clin Invest, 2012, 122(8): 2916-2927.

[20]

Naito N, Kawano H, Isomura Y, et al. The antifibrotic effects of α9 integrin-targeted therapy through inhibition of fibrocyte and fibroblast activity[J]. Am J Respir Crit Care Med, 2025, 211(Supplement_1): A4723.

[21]

Xing C, Bao L, Li W, et al. Progress on role of ion channels of cardiac fibroblasts in fibrosis [ J ]. Front Physiol, 2023, 14: 1138306.

[22]

Wu X, Yang Y . Neutrophil extracellular traps (NETs) and fibrotic diseases[J]. Int Immunopharmacol, 2024, 133: 112085.

[23]

Tu Q, Gong X, Yuan X, et al. NETs drive myocardial fibrosis in hypertension via an NF-κB/ ferroptosis axis [J]. Front Immunol, 2026, 16: 1712786.

[24]

Jiang Y, Jiang R, Xia Z, et al. Engineered neutrophil membrane-camouflaged nano complexes for targeted siR- NA delivery against myocardial ischemia reperfusion inju- ry[J]. J Nanobiotechnol, 2025, 23(1): 134.

[25]

Chang X, Liu R, Li R, et al. Molecular mechanisms of mitochondrial quality control in ischemic cardiomyopathy [J]. Int J Biol Sci, 2023, 19(2): 426-448.

[26]

Li F, Du W W, Li X, et al. A novel circular RNA cir- cITGa9 predominantly generated in human heart disease induces cardiac remodeling and fibrosis[J]. Research, 2024, 7: 303.

[27]

Deng M, Ma R, Li J, et al. Butein attenuates cardiac fi- brosis by mediating TGF-β1/ Smad signaling pathway af- ter myocardial infarction [J]. J Mol Histol, 2025, 56 (6): 352.

[28]

Liu B C, Lan H Y, Lv L L . Renal Fibrosis: Mechanisms and Therapies [ M ]. Singapore: Springer Singapore, 2019.

[29]

Lee H, Fessler M B, Qu P, et al. Macrophage polariza- tion in innate immune responses contributing to pathogen- esis of chronic kidney disease[J]. BMC Nephrol, 2020, 21(1): 270.

[30]

Wang Y, Zhang J, Yang Z, et al. Ocotillol-type pseudo- ginsenoside-F11 alleviates lipopolysaccharide-induced a- cute kidney injury through regulation of macrophage func- tion by suppressing the NF-κB/ NLRP3/ IL-1β signaling pathway[J]. J Agric Food Chem, 2024, 72 (37 ): 20496-20512.

[31]

王亚茹. 奥克梯隆型人参皂苷调控巨噬细胞功能抗肾纤维化的作用及机制研究[ D]. 长春: 吉林大学, 2024.

[32]

Wang Y R. Ocotillol-type ginsenosides ameliorate renal fi- brosis byregulating of macrophage function[ D]. Chang- chun: Jilin University, 2024.

[33]

Kashiwagi A, Maegawa H . Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhib- itors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus [J]. J Diabetes Invest, 2017, 8(4): 416-427.

[34]

He S, Wang Z, Zhu Y, et al. Elucidating the immuno- modulatory roles and mechanisms of CUL4B in the im- mune system: a comprehensive review[J]. Front Immu- nol, 2025, 16: 1473817.

[35]

Jin S, Song Y, Zhou L, et al. Depletion of CUL4B in macrophages ameliorates diabetic kidney disease via miR- 194-5p/ ITGA9 axis [ J ]. Cell Rep, 2023, 42 (6): 112550.

[36]

Melchinger I, Guo K, Li X, et al. VCAM-1 mediates proximal tubule-immune cell cross talk in failed tubule recovery during AKI-to-CKD transition[J]. Am J Physiol Renal Physiol, 2024, 327(4): F610-F622.

基金资助

*吉林省科技发展项目(YDZJ202501ZYTS036, 20250204074YY)

大学生创新创业省级项目(S202410183699)

AI Summary AI Mindmap
PDF (1225KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉